Update on PDE-5 Inhibitors: Safety, New PDE-5 Inhibitors, Over-the-Counter PDE-5 Inhibitors?

[madman]

​

"Princeton 4: PDE5 Inhibitors and Cardiac Health Symposium.”​

Selected lectures that examine the intersection between sexual health and cardiovascular health, with a focus on the pharmacologic therapy for erectile dysfunction (ED). Lectures from US experts on the newest data on safety and cardiac interactions with PDE5 inhibitors, the workup for ED and associated cardiac risk factors in 2023, the role of CT Calcium scoring, the psychologic impact of ED, potential cardioprotective effects of PDE5 inhibitors, mechanism of action of PDE5 inhibitors, non-PDE5 inhibitor therapy for ED including restorative therapies (stem cell, shock wave therapy, platelet rich plasma), alternative therapies, PDE5 inhibitors in women, status of diagnostic and treatments for female sexual dysfunction.

 

[madman]

 

[madman]

 

[madman]

 

[madman]

 

[madman]

 

[madman]

 

[madman]

 

[madman]

 

[madman]

 

[madman]

 

[madman]

 

[madman]

 

[Dr.V.P.C.]

Here in Brazil all Pde5 are over the counter.

 

[madman]

Thread 'Tadalafil Use in Cardiovascular Disease'

Mar 2, 2025

Abstract

Tadalafil is a phosphodiesterase inhibitor currently approved for use in erectile dysfunction (ED), benign prostatic hyperplasia (BPH), and pulmonary arterial hypertension (PAH). While tadalafil’s benefits in ED and BPH have been well-established for years, its benefits in PAH were identified only recently in major clinical trials, resulting in the recent approval of a single tablet, combination therapy of tadalafil with an endothelin receptor antagonist for PAH. With Tadalafil’s cardiovascular benefits in ED, BPH, and PAH, clinical researchers have begun investigating...

• madman
• tadalafil; nitric oxide; cvd; ed; pah
• Replies: 5
• Forum: Health & Wellness